A San Ramon, California medical device company treating congestive heart failure patients is seeking $4 million, according to a regulatory filing.
CHF Technologies, which does business as BioVentrix, has already raised $767,340. BioVentrix is developing catheter-based approaches to managing congestive heart failure.
The company has built the Revivent Myocardial Anchoring System, which aims to improve cardiac function by restoring the size and volume of the left ventricle in heart patients. The system uses a therapy that excludes the scarred, nonfunctioning portion of the left ventricle to enhance its efficiency. The Revivent system, a surgical product, is not available for commercial use so far given that it is undergoing clinical evaluation. So far, clinical studies show that the therapy works, according to the company’s website.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
BioVentrix is now trying to effect the same left ventricle functional improvement using an endovascular, transcatheter approach.
The company’s board of directors includes Steven Healy, president of Zimmer Spine.
Here’s a video of the Revivent Myocardial Anchoring System:
